Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
- Molecular Response
- 10865 Road to the Cure
- San Diego CA, 92121
- UNITED STATES
Molecular Response is an oncology-focused CRO, with a viable primary tumor bank of more than 140,000 clinical biopsies, spanning 76 diagnoses. Tumors are employed to create Patient-Derived Xenograft (PDX) models, 3D cell culture for ex-vivo pharmacology studies, and genomic surveys for target prevalence. Tumors have histology/pathology reports, ex-vivo drug resistance data and matched FFPE blocks. These platforms allow for in vivo and ex-vivo drug candidate selection, patient stratification, biomarker verification, and development of Companion Diagnostic assays in CAP/CLIA-accredited labs.